{"id":9051,"date":"2020-04-16T18:19:25","date_gmt":"2020-04-16T12:49:25","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=9051"},"modified":"2023-02-10T12:33:07","modified_gmt":"2023-02-10T07:03:07","slug":"recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics","title":{"rendered":"Vir&#8217;s drug shows results; Abbott launches coronavirus antibody lab test; Reprogrammed skin cells repair vision in mouse models; Moma Therapeutics focuses for molecular machines"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fcd95ab0458\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fcd95ab0458\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics\/#Virs_Hepatitis_B_drug_shows_positive_results_in_phase_2\" >Vir&#8217;s&nbsp;Hepatitis&nbsp;B drug shows positive results in phase 2<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics\/#Abbott_launches_coronavirus_antibody_lab_test\" >Abbott launches coronavirus antibody lab test<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics\/#Reprogrammed_skin_cells_repair_vision_in_mouse_models\" >Reprogrammed skin cells repair vision in mouse models&nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics\/#Moma_Therapeutics_focuses_on_molecular_machines\" >Moma Therapeutics focuses on molecular machines&nbsp;<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-vir-s-hepatitis-b-drug-shows-positive-results-in-phase-2\"><span class=\"ez-toc-section\" id=\"Virs_Hepatitis_B_drug_shows_positive_results_in_phase_2\"><\/span><strong>Vir&#8217;s&nbsp;Hepatitis&nbsp;B drug shows positive results in phase 2<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-b-virus-hbv-infection-market\">hepatitis B<\/a> drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the <a href=\"https:\/\/www.delveinsight.com\/report-store\/hepatitis-b-epidemiology-forecast\">hepatitis B<\/a> surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs.<\/p>\n\n\n\n<p>The drug, VIR-2218, is made to prevent the expression of all hepatitis B proteins, including its surface antigen, HBsAg. The prospect was called ALN-HBV-02 before Alnylam licensed it to Vir in 2017 as a part of an infectious disease agreement which is worth up to USD 1 billion.<\/p>\n\n\n\n<p>The study tried four dose levels of VIR-2218 in 24 patients who were getting nucleos(t)ide reverse transcriptase inhibitor therapy to prevent the hep B virus from replicating. The patients received two doses of the drug\u201420, 50, 100 or 200 mg\u2014a month apart. After half a year, all four doses led to reductions in HBsAg, the surface antigen that displays whether a person is infected with hepatitis B. The size of the effect grew with the size of the dose, with the 200-mg dose performing the best.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbott-launches-coronavirus-antibody-lab-test\"><span class=\"ez-toc-section\" id=\"Abbott_launches_coronavirus_antibody_lab_test\"><\/span><strong>Abbott launches coronavirus antibody lab test<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>After developing a high-throughput assay and a quick point-of-care test, Abbott is now launching its third <a href=\"https:\/\/www.delveinsight.com\/blog\/coronavirus\"><strong>COVID-19<\/strong><\/a> diagnostic, aimed at detection of a person&#8217;s antibodies to the novel coronavirus.<\/p>\n\n\n\n<p>The blood test is designed to be run in a centralized laboratory using the company&#8217;s Architect analyzer hardware, which Abbott informed that it is already in use at about 2,000 U.S. facilities and can give between 100 and 200 results per hour. The device maker also schedules to expand the use of the test to its newer line of Alinity instruments.<\/p>\n\n\n\n<p>Serology tests like these can be utilized to deliver a deeper understanding of the virus&#8217;s spread and can notify whether a person has previously had the disease or not. This could also help estimate how long protective antibodies last within the body following an infection. The test specifically recognizes the standard bloodstream antibody immunoglobulin G or IgG.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-reprogrammed-skin-cells-repair-vision-in-mouse-models\"><span class=\"ez-toc-section\" id=\"Reprogrammed_skin_cells_repair_vision_in_mouse_models\"><\/span><strong>Reprogrammed skin cells repair vision in mouse models&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The loss of light-sensing cells in the retina called photoreceptors is related to several eye diseases, including <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/age-related-macular-degeneration-amd-market\" class=\"ek-link\">age-related macular degeneration (AMD)<\/a><\/strong>, which is a leading cause of blindness in older age. Many approaches have done to restore light-sensing cells that have coaxed stem cells to become photoreceptors.<\/p>\n\n\n\n<p>The researchers at National Institutes of Health&#8217;s National Eye Institute (NEI) have developed a new technique that they contemplate could be used to reinstate photoreceptors without stem cells. They utilize the chemicals to transform skin cells squarely into rod photoreceptors as reported in the journal- Nature.<\/p>\n\n\n\n<p>The researchers commenced by bathing skin cells in five chemicals known to mediate the molecular pathways of photoreceptors. That led to cells that looked and functioned like rod photoreceptors\u2014and that were set to be implanted into mice in 10 days. It was a quicker process than the six months or so that it takes to persuade induced pluripotent stem cells to transform into photoreceptors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-moma-therapeutics-focuses-on-molecular-machines\"><span class=\"ez-toc-section\" id=\"Moma_Therapeutics_focuses_on_molecular_machines\"><\/span><strong>Moma Therapeutics focuses on molecular machines&nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Moma Therapeutics received USD 86 million from the likes of Third Rock Ventures to go after molecular machines methodically, a family of more than 400 enzymes that others have only got by chance.<\/p>\n\n\n\n<p>Molecular machines are a prosperous target class that function to move things around the cell, utilizing the energy that comes from the hydrolysis of ATP as said by Tim Guzi, Ph.D., Moma&#8217;s drug discovery chief. They range from DNA helicases and chromatin remodelers that govern genetic expression, to transporters, which transfers materials inside cells and across membranes.<\/p>\n\n\n\n<p>Others have drugged molecular machines before, including Vertex Pharmaceuticals that has developed multiple drugs that target a transporter, which causes cystic fibrosis due to mutations in the gene that encodes it. The drugs that are approved Kalydeco (ivacaftor) as well as gastroesophageal reflux disease (GERD) med omeprazole and chemo drug etoposide highlight the promise of Moma&#8217;s approach.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Vir&#8217;s&nbsp;Hepatitis&nbsp;B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218, is made to prevent the expression of all [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":9053,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":2,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2405,1299,1964,18238,420,639,5789,18237],"industry":[17225],"therapeutic_areas":[17233],"class_list":["post-9051","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-abbott","tag-age-related-macular-degeneration","tag-hepatitis-b","tag-moma-therapeutics","tag-news","tag-pharma-news","tag-recent-pharma-news","tag-vir","industry-pharmaceutical","therapeutic_areas-hematological-disorders"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Vir Biotech., Abbott, Moma Therapeutics, NEI<\/title>\n<meta name=\"description\" content=\"Vir\u2019s VIR-2218 results; Abbott&#039;s coronavirus antibody lab test; Moma Therapeutics&#039;s molecular machines; Reprogrammed skin cells repair vision\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Vir Biotech., Abbott, Moma Therapeutics, NEI\" \/>\n<meta property=\"og:description\" content=\"Vir\u2019s VIR-2218 results; Abbott&#039;s coronavirus antibody lab test; Moma Therapeutics&#039;s molecular machines; Reprogrammed skin cells repair vision\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-16T12:49:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-02-10T07:03:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/16181638\/blog-image.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Vir Biotech., Abbott, Moma Therapeutics, NEI","description":"Vir\u2019s VIR-2218 results; Abbott's coronavirus antibody lab test; Moma Therapeutics's molecular machines; Reprogrammed skin cells repair vision","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Vir Biotech., Abbott, Moma Therapeutics, NEI","og_description":"Vir\u2019s VIR-2218 results; Abbott's coronavirus antibody lab test; Moma Therapeutics's molecular machines; Reprogrammed skin cells repair vision","og_url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2020-04-16T12:49:25+00:00","article_modified_time":"2023-02-10T07:03:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/16181638\/blog-image.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics","url":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics","name":"Pharma News | Vir Biotech., Abbott, Moma Therapeutics, NEI","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/16181638\/blog-image.jpg","datePublished":"2020-04-16T12:49:25+00:00","dateModified":"2023-02-10T07:03:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Vir\u2019s VIR-2218 results; Abbott's coronavirus antibody lab test; Moma Therapeutics's molecular machines; Reprogrammed skin cells repair vision","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/recent-pharma-happenings-for-vir-biotech-abbott-moma-therapeutics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/16181638\/blog-image.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/16181638\/blog-image.jpg","width":772,"height":482,"caption":"pharma news"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2020\/04\/16181638\/blog-image-300x187.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Abbott<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">hepatitis B<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Moma Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">recent pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Vir<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abbott<\/span>","<span class=\"advgb-post-tax-term\">Age-related\u00a0macular degeneration<\/span>","<span class=\"advgb-post-tax-term\">hepatitis B<\/span>","<span class=\"advgb-post-tax-term\">Moma Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">news<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">recent pharma news<\/span>","<span class=\"advgb-post-tax-term\">Vir<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 6 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 16, 2020","modified":"Updated on Feb 10, 2023"},"absolute_dates_time":{"created":"Posted on Apr 16, 2020 6:19 pm","modified":"Updated on Feb 10, 2023 12:33 pm"},"featured_img_caption":"pharma news","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9051","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=9051"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/9051\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/9053"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=9051"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=9051"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=9051"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=9051"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=9051"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}